Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for ET-700 (Extended-Release Drug) in Undisclosed Indication. The expected timing is based on the latest available company guidance and may change.
05/14/26:- ET-700 first patient dosed. Topline results are expected H2 2026. Pivotal study is possible early 2027. 08/13/26:- ET-700 pilot study is underway. Pivotal study initiation is expected in Early 2027 if results succeed.
Verification
Confirm timing and program details against the company announcement or filing.